Global Rare Biomarkers Specimen Collection And Stabilization Market Projected to Surpass $52.46 Billion by 2029 with 10.3% Annual Growth

"What Are the Market Size and Growth Forecast for the Rare Biomarkers Specimen Collection And Stabilization Market?
The market for the collection and stabilization of rare biomarkers specimens has seen a quick expansion in recent years. Its size is projected to increase from $32.01 billion in 2024 to $35.4 billion in 2025, with a compound annual growth rate (CAGR) of 10.6%. This surge in the previous period can be associated with factors such as the human genome project, a rise in cancer research, increased investment in pharmaceutical R&D, the growth of genomics and proteomics, and enhanced management of bioinformatics and data.

The market size for the collection and preservation of rare biomarkers specimens is set to experience speedy expansion in the upcoming years. It is projected to reach $52.46 billion by 2029, with a compound annual growth rate (CAGR) of 10.3%. The augmentation during the forecast period is linked to a surge in the applications of liquid biopsy, better public understanding and demand, growing acceptance of non-invasive practices, and the discovery of biomarkers in rare diseases. The major trends predicted for the forecast period include progress in preservation technologies, an increase in genomic and proteomic research, the development of point-of-care testing, regulatory advancements and standardization, as well as improved data analytics and AI integration.

What Are the Key Drivers Behind the Growth of the Rare Biomarkers Specimen Collection And Stabilization Market?
The growth of the rare biomarker specimen collection and stabilization market is anticipated to be fueled by the rising incidence of cancer. Cancer refers to a collection of diseases that are characterized by the unchecked multiplication and spreading of abnormal cells. The increasing incidence of cancer is attributed to environmental contaminants and lifestyle factors such as smoking and poor dietary habits, which have the potential to amplify genetic susceptibilities. The application of rare biomarker specimen collection and stabilization techniques in the investigation of cancer prevalence allows for more precise identification and surveillance of specific types of cancer, resulting in improved diagnostic and treatment strategies. For example, a report from the European Commission, a governing body based in Europe, disclosed that new cancer instances had risen to 2.74 million in 2022, showing a 2.3% increase from 2020, in October 2023. Consequently, the rising incidence of cancer is fostering the expansion of the rare biomarker specimen collection and stabilization market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp

Which Key Market Leaders Are Driving Rare Biomarkers Specimen Collection And Stabilization Industry Growth?
Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC

What Are the Emerging Trends in the Rare Biomarkers Specimen Collection And Stabilization Industry?
Major firms in the rare biomarker specimen collection and stabilization market are prioritizing the development of groundbreaking solutions like an automated pre-analytical platform for multiomic liquid biopsy preparation from plasma and cell samples. The pre-analytical platform delivers automated fresh sample preparation at the time of blood collection, allowing unattended processing of whole blood samples without the requirement for specific tubes or trained personnel, hence ensuing sample preservation. For instance, Tethis S.p.A., a biotech company from Italy, introduced See.d in May 2022. This platform is the industry's first completely automated, standardized pre-analytical system, boasting unique features such as precise sample management, efficient plasma separation for cellular fractions, and SmartBioSurface slides for white blood cell fixation. It also includes an objective quality control evaluation system for sample stability. By using such a platform, proteomics and metabolomics data sets can be systematically scored to assess plasma and serum sample stability.

What Are the Main Segments in the Rare Biomarkers Specimen Collection And Stabilization Market?
The rare biomarkers specimen collection and stabilization market covered in this report is segmented -

1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA), Circulating Tumor Cells (CTCs), Exosomes or Extracellular Vesicles
2) By Specimen: Serum Or Plasma, Other Specimens
3) By Application: Non-Invasive Prenatal Testing (NIPT), Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Other Applications
4) By End-User: Hospitals, Perinatal Clinics, Public Health Labs, Private Or Commercial Labs, Physician Labs, Research Institutes, Other End-Users

Subsegments:
1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA, Serum CCFDNA
2) By Circulating Tumor Cells (CTCs): CTCs In Blood, CTCs In Bone Marrow
3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma, Exosomes From Serum

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/rare-biomarkers-specimen-collection-and-stabilization-global-market-report

Which Geographic Area Leads the Rare Biomarkers Specimen Collection And Stabilization Market?
North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Is Covered In The Rare Biomarkers Specimen Collection And Stabilization Global Market Report?

- Market Size Analysis: Analyze the Rare Biomarkers Specimen Collection And Stabilization Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Rare Biomarkers Specimen Collection And Stabilization Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Rare Biomarkers Specimen Collection And Stabilization Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Rare Biomarkers Specimen Collection And Stabilization Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15913

"

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
•LinkedIn: https://in.linkedin.com/company/the-business-research-company
•Twitter: https://twitter.com/tbrc_info
•YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.